Prognostic factors in acute myeloid leukaemia

2001 ◽  
Vol 14 (1) ◽  
pp. 65-75 ◽  
Author(s):  
Bob Löwenberg
2011 ◽  
Vol 139 (5-6) ◽  
pp. 347-352 ◽  
Author(s):  
Nebojsa Antonijevic ◽  
Nada Suvajdzic ◽  
Tatjana Terzic ◽  
Branko Jakovljevic ◽  
Gradimir Jankovic ◽  
...  

Introduction. Therapy related acute myeloid leukaemia (t-AML) is a distinct clinical entity recognized by the World Health Organization classification occurring after chemotherapy and/or radiation treatment administered for a previous disease. T-AML is characterised by pancytopenia, three-lineage myelodysplasia, high frequency of unfavourable cytogenetics and short survival. Objective. The aim of this study was to analyse clinical, cytogenetic, and cytological characteristics of t-AML and their impact on survival. Methods. Seventeen patients with t-AML (8 male and 9 female; median age 59 years) were identified among 730 consecutive patients with acute myeloid leukaemia. The degree of three-lineage dysplasia as well as haematological, cytological and cytogenetic analyses, were assessed by standard methods. Results. The patients survived a median of 62.5 days with the 10% probability of survival during two years. Prognostically favourable factors were a higher percentage of dysplastic granulocytic cells, age less than 60 years, and presence of prognostically favourable karyotype inv(16), t(15;17), t(8;21). Conclusion. The stated prognostic factors that include age, cytogenetics findings and granulocytic dysplasia analysis could contribute to adequate risk stratification of t-AML, though fuller results would require additional analyses.


2014 ◽  
Vol 168 (1) ◽  
pp. 94-101 ◽  
Author(s):  
Seth E. Karol ◽  
Elaine Coustan-Smith ◽  
Xueyuan Cao ◽  
Sheila A. Shurtleff ◽  
Susana C. Raimondi ◽  
...  

1998 ◽  
Vol 77 (12) ◽  
pp. 2298-2303 ◽  
Author(s):  
N Wakimoto ◽  
A Yokoyama ◽  
J Okabe-Kado ◽  
N Nagata ◽  
K Motoyoshi ◽  
...  

Author(s):  
Gertjan Kaspers ◽  
Dirk Reinhardt

Acute myeloid leukaemia (AML) is the second most frequent type of leukaemia in children, and is cured nowadays in about 75% of patients in settings with essentially unlimited resources. This chapter discusses the aetiology and epidemiology of this interesting disease, its typical clinical presentation, diagnostics, and biology. The classifications, prognostic factors, and risk stratification (including minimal residual disease), and AML treatment (covering chemotherapy and allogeneic stem-cell transplantation) is presented. Several practical illustrations are included, and results of recent studies from the main cooperative study groups are summarized. Finally, side effects during treatment and late effects, as well as acute promyelocytic leukaemia (APL) and myeloid leukaemia of Down syndrome (ML-DS), are discussed. The chapter concludes with the actual challenges and perspectives.


2014 ◽  
Vol 165 (1) ◽  
pp. 17-38 ◽  
Author(s):  
Ruediger Liersch ◽  
Carsten Müller-Tidow ◽  
Wolfgang E. Berdel ◽  
Utz Krug

Sign in / Sign up

Export Citation Format

Share Document